Oncology

Precision Oncology in Australia: insights from Prof David Thomas

In partnership with industry and government, Omico launched the pioneering initiative PrOSPeCT in July 2023, aimed at integrating comprehensive genomic profiling (CGP) into standard oncology care in Australia. To date, Omico has provided CGP to over 15,000 patients, of whom more than 1,600 have received matched therapies primarily through accelerated access to clinical trials. Professor […]

Precision Oncology in Australia: insights from Prof David Thomas Read More »

Advancing women’s health: key takeaways from AOGIN 2024

Advancing women’s health: key takeaways from AOGIN 2024

The Asia-Oceania Research Organisation in Genital Infection and Neoplasia (AOGIN) recently held its bi-annual conference in Seoul, South Korea, with the theme “Empowering Women, Together against Cervical Cancer”. Despite having many tools that can prevent, screen for and treat cervical cancer, the conference opened with a powerful statement: “Every two minutes, a woman dies of

Advancing women’s health: key takeaways from AOGIN 2024 Read More »

Prof Dietmar Schmidt on improving cervical cancer screening algorithms with p16/Ki67 dual stain biomarkers

Speaking at EUROGIN 2024, Prof Dietmar Schmidt, Consultant Pathologist at MVZ Histology, Cytology and Molecular Diagnostics, talks about the benefits of using p16/Ki67 dual staining biomarkers as a predictor of risk for HPV-positive patients. Now with routine vaccination programmes being implemented alongside HPV primary screening in many countries, experts are looking to optimise the triage

Prof Dietmar Schmidt on improving cervical cancer screening algorithms with p16/Ki67 dual stain biomarkers Read More »

Optimising screening and triage for cervical cancer: Prof Mark Stoler on why biomarkers are best

Optimising screening and triage for cervical cancer: Prof Mark Stoler on why biomarkers are best

At the 35th International Papillomavirus Conference (IPVC) in April 2023, Prof Mark Stoler of the University of Virginia Health System spoke about detecting p16 and Ki-67, two biomarkers that indicate the presence of transforming HPV infections. His talk assesses their efficacy to definitively show the presence of HPV infection in a patient, showing how the

Optimising screening and triage for cervical cancer: Prof Mark Stoler on why biomarkers are best Read More »

How Peru broke down barriers to cervical cancer screening

How Peru broke down barriers to cervical cancer screening_thumbnail

At the 35th International Papillomavirus Conference (IPVC) in April 2023, Dr Gino Venegas of the Department of Gynaecologic Oncology at the Angloamericana Clinic in Lima shares how Peru tackled cervical cancer by addressing numerous barriers to screening, such as lack of awareness, affordability challenges, limited political commitment to progress, and social stigma around HPV testing.

How Peru broke down barriers to cervical cancer screening Read More »

Co-creating digital solutions to support cervical cancer screening

co-creating digital solutions_thumbnail

The World Health Organisation strongly encourages the use of digital technologies to support the cervical cancer elimination efforts that are underway in many countries around the world. At the 35th International Papillomavirus Conference (IPVC) in April 2023, Dr Luis Riba of Roche Diagnostics described how digital solutions can account for key challenges in cervical cancer

Co-creating digital solutions to support cervical cancer screening Read More »

Implementing p16/ki67 dual stain at a large US commercial lab: Dr Tamera Paczos

Implementing p16/ki67 dual stain at a large US commercial lab: Dr Tamera Paczos

As Vice President and Associate Chief Medical Officer at BioReference Laboratories, one of the largest clinical labs in the United States, Dr Tamera Paczos oversaw the addition of p16/Ki-67 dual staining assays to the lab’s assay portfolio. In the US, these assays are used in triage to further risk stratify women who have come for

Implementing p16/ki67 dual stain at a large US commercial lab: Dr Tamera Paczos Read More »

Prof Mark Stoler on HPV primary screening with biomarker based triage

Prof Mark Stoler on HPV primary screening with biomarker based triage_thumbnail

While cervical cancer is preventable, an estimated 14,000 new cases are diagnosed in the United States every year, leading to almost 4,300 deaths from the disease. As Professor Emeritus of Pathology and Clinical Gynaecology at the University of Virginia Health System, Prof Mark Stoler is working towards preventing these deaths.  In this talk at the

Prof Mark Stoler on HPV primary screening with biomarker based triage Read More »

Dr Sharad Paul on skin health, cancer, and the evolving role of pathology

Dr Sharad Paul on skin health, cancer and the evolving role of pathology_thumbnail

Dr Sharad Paul is a New Zealand-based skin cancer specialist, social entrepreneur, and author. In this Q&A with Chitra Nair, APAC Pathology Lead at Roche Diagnostics Asia Pacific, he shares his thoughts on key issues in skin health management and what they mean for the practice of laboratory medicine, drawing upon his vast clinical experience,

Dr Sharad Paul on skin health, cancer, and the evolving role of pathology Read More »

Scroll to Top